Lucid Diagnostics (LUCD) Share-based Compensation Growth (1y) (2021 - 2026)
Lucid Diagnostics (LUCD) Share-based Compensation Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 9.69% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 37.62% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 6.74% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 12.16% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 12.94% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | - |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -30.44% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 59.09% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Lucid Diagnostics | 133.09 Mn | 105.22 Mn | -325,000.00 | -97.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -97.09% |
| Dec 31, 2025 | -22.33% |
| Sep 30, 2025 | -6.19% |
| Jun 30, 2025 | -4.83% |
| Mar 31, 2025 | 38.63% |
| Dec 31, 2024 | 55.76% |
| Sep 30, 2024 | -1.92% |
| Jun 30, 2024 | -14.15% |
| Mar 31, 2024 | -73.62% |
| Dec 31, 2023 | -72.39% |
| Sep 30, 2023 | -64.94% |
| Jun 30, 2023 | -63.61% |
| Mar 31, 2023 | -26.54% |
| Dec 31, 2022 | -1.86% |
| Sep 30, 2022 | 28.82% |
| Jun 30, 2022 | 48.99% |
| Mar 31, 2022 | 376.40% |
| Dec 31, 2021 | 22,243.77% |
| Sep 30, 2021 | 16,838.59% |